Results 71 to 80 of about 8,578 (238)

Inter‐Nanoparticle FRET for Biosensing: Photophysics Versus Size

Angewandte Chemie International Edition, Volume 64, Issue 39, September 22, 2025.
Förster resonance energy transfer (FRET) systems with luminescent nanoparticles (NPs) as donors and acceptors (inter‐NP FRET) combine unique photophysical properties with large sizes. This review discusses the influence of NP type, architecture, surface chemistry, and optical properties on FRET and the pros and cons of inter‐NP FRET for bioanalytical ...
Eduard Madirov, Clara Catros, Niko Hildebrandt, Chloé Grazon   +3 more
wiley   +1 more source

The Therapeutic Potential of Photoimmunotherapy as a Safe, Effective and Non‐Toxic Treatment Option for Superficial Triple Negative Breast Cancer

Cancer Medicine, Volume 14, Issue 18, September 2025.
ABSTRACT Triple‐negative breast cancer (TNBC) is the most aggressive breast cancer subtype, lacking estrogen (ER), progesterone (PR), and human epidermal growth factor receptor (HER‐2) expression. It disproportionately affects women of African descent and has a poor clinical prognosis attributed to its acute heterogeneity, thereby causing elevated ...
Fleury Augustin Nsole Biteghe, Neelakshi Mungra, Zaria Malindi, Nyangone Ekome Toung Chalomie, Ketum Ateh Stanislas, Sayeda Yasmin‐Karim, G. Mike Makrigiorgos, Fallon Ester Chipidza, Olusiji Alex Akinrinmade, Srinivas Sridhar, Stefan Barth, Wilfred Ngwa   +11 more
wiley   +1 more source

Enhanced diagnostic potential of CSPG4 in melanoma and nevi: a comparative study with PRAME, CDC7 and Ki67

The Journal of Pathology, Volume 267, Issue 1, Page 69-78, September 2025.
Abstract Chondroitin sulfate proteoglycan 4 (CSPG4) is a promising target for melanoma immunotherapy, but its expression in benign melanocytic lesions and its diagnostic value remain unexplored. This study assessed CSPG4 expression in benign nevi (BN), dysplastic nevi (DN), and superficial spreading melanomas (SSM), comparing it with PRAME ...
Elias A T Koch, Christina Seidel, Ramona Erber, Michael Erdmann, Markus V Heppt, Stefan Schliep, Carola Berking, Jan Dörrie, Niels Schaft   +8 more
wiley   +1 more source

Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders

, 2011
The year 1997 was pivotal in lymphoma research, as it was the year that the US FDA approved rituximab. Rituximab significantly altered clinical management and outcomes of patients with B-cell malignancies.
Myron S Czuczman, Lyudmyla Derby
core   +1 more source

Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer

Nature Communications, 2018
One of the major obstacles in nanoparticle-based therapy is to achieve tumour targeting, limiting non-specific accumulation of the nanoparticles. Here the authors propose the conjugation of anti-HER2 scFv fragments to the silica nanoparticles, increasing
Feng Chen, Kai Ma, Brian Madajewski, Li Zhuang, Li Zhang, Keith Rickert, Marcello Marelli, Barney Yoo, Melik Z. Turker, Michael Overholtzer, Thomas P. Quinn, Mithat Gonen, Pat Zanzonico, Anthony Tuesca, Michael A. Bowen, Larry Norton, J. Anand Subramony, Ulrich Wiesner, Michelle S. Bradbury   +18 more
doaj   +1 more source

Evaluation of Radiolabeled Girentuximab In Vitro and In Vivo

Pharmaceuticals, 2018
Girentuximab (cG250) targets carbonic anhydrase IX (CAIX), a protein which is expressed on the surface of most renal cancer cells (RCCs). cG250 labeled with 177Lu has been used in clinical trials for radioimmunotherapy (RIT) of RCCs.
Tais Basaco, Stefanie Pektor, Josue M. Bermudez, Niurka Meneses, Manfred Heller, José A. Galván, Kayluz F. Boligán, Stefan Schürch, Stephan von Gunten, Andreas Türler, Matthias Miederer   +10 more
doaj   +1 more source

Cell Internalization Studies of Gadofullerene-(ZME-018) Immunoconjugates into A375m Melanoma Cells

, 2011
Fullerene (C60)-monoclonal antibody (mAb) immunoconjugates have been determined to internalize into target cells using water-soluble Gd3+ ion-filled metallofullerenes (Gd@C60[OH]x). Two separate conjugations of Gd@C60(OH)x with the antibody ZME-018 and a
Wilson, Lon J., Marks, John W., Bolskar, Robert D., Berger, Christopher Scott, Rosenblum, Michael G.   +4 more
core   +1 more source

Identification of potential cell surface targets in patient‐derived cultures toward photoimmunotherapy of high‐grade serous ovarian cancer

Photochemistry and Photobiology, Volume 101, Issue 5, Page 1211-1231, September/October 2025.
Through mRNA sequencing, proteomics, and flow cytometry, we identified potential cell surface targets toward tumor‐targeted, activatable photoimmunotherapy (taPIT) in advanced high‐grade serous ovarian cancers (HGSOCs) with low EGFR expression. The reliance on EGFR overexpression has been a major limitation of taPIT, which this study seeks to address ...
Sudip Timilsina, Anish Raju Amara, Rafay Abu, Bryan Q. Spring   +3 more
wiley   +1 more source

Comparative Efficacy of Ribosome-Inactivating Protein-Containing Immunotoxins in 2D and 3D Models of Sarcoma

Toxins
Sarcomas are very complex and clinically challenging mesenchymal tumors. Although the standard therapeutic approach has improved the 5-year survival rate, many patients experience local relapses and/or distant metastases.
Giulia Calafato, Massimo Bortolotti, Letizia Polito, Andrea Bolognesi   +3 more
doaj   +1 more source

Chemoenzymatic Strategy for the Synthesis of Site-Specifically Labeled Immunoconjugates for Multimodal PET and Optical Imaging

Bioconjugate chemistry, 2014
The complementary nature of positron emission tomography (PET) and optical imaging (OI) has fueled increasing interest in the development of multimodal PET/OI probes that can be employed during the diagnosis, staging, and surgical treatment of cancer ...
Brian M. Zeglis, C. B. Davis, Dalya Abdel-Atti, S. Carlin, Aimei Chen, R. Aggeler, B. Agnew, Jason S. Lewis   +7 more
semanticscholar   +1 more source